Wells Fargo Cautious on Praxis Precision (PRAX) After Recent Revenue Estimates

Group 1 - Praxis Precision Medicines Inc. (NASDAQ:PRAX) is recognized as one of the 13 stocks with significant upside potential, with Wells Fargo initiating coverage with an Equal Weight rating and a price target of $282, while noting a 50% probability of success for its investigational drug ulixacaltamide [1][3] - The company anticipates potential peak revenue of up to $20 billion over the next 24 months from four drugs, including $10 billion from ulixacaltamide, $5 billion from relutrigine, $4 billion from vormatrigine for epilepsy, and around $1 billion from elsunersen [2] - Praxis is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance [3]